ChemicalBook > Product Catalog >API >Antineoplastic agents >Tinib Antineoplastic drugs >Axitinib


Axitinib Suppliers list
Company Name: Jinan Xinke Pharmaceutical Sci.&Tech. Co.,Ltd.
Tel: +8613256107535
Products Intro: Product Name:Axitinib
Purity:99% Package:1KG;USD
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Products Intro: Product Name:Axitinib
Purity:99.00% Package:100g,500g,1KG,10KG,100KG
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd.
Tel: +86-10-60279497 +86(0)15646567669
Products Intro: Product Name:Axitinib
Purity:98%99% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: Product Name:319460-85-0
Purity:0.99 Package:25KG,5KG;1KG;500G
Tel: +86 21 5161 9050/ 5187 7795
Products Intro: CAS:319460-85-0
Purity:98% HPLC Package:5G;10G;25G;50G;100G;250G;1KG

Lastest Price from Axitinib manufacturers

  • Axitinib
  • US $0.00 / KG
  • 2020-02-19
  • CAS:319460-85-0
  • Min. Order: 100g
  • Purity: 99%
  • Supply Ability: 10kg/Month
  • Axitinib
  • US $0.00-0.00 / 公斤
  • 2020-01-17
  • CAS: 319460-85-0
  • Min. Order: 100G
  • Purity: 99.0%+
  • Supply Ability: 100 tons
  • Axitinib
  • US $10.00 / KG
  • 2019-12-02
  • CAS:319460-85-0
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 10 mt
Axitinib Basic information
FDA approved axitinib use of treating advanced kidney cancer
Product Name:Axitinib
Synonyms:Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-;N-METHYL-2-{[3-((E)-2-PYRIDIN-2-YLVINYL)-1H-INDAZOL-6-YL]SULFANYL}BENZAMIDE;N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide;AVERMECTINB;Axitinib for research;AG 013736;N-Methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide;Axitinib cas 319460-85-0 (whatsapp:+8618830163278)
Product Categories:API-;Pharmaceuticals;Protein Kinase Inhibitors and Activators;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;chemical-;Pfizer compounds;API;AG 013736
Mol File:319460-85-0.mol
Axitinib Structure
Axitinib Chemical Properties
Melting point 213-215°C
Boiling point 668.9±55.0 °C(Predicted)
density 1.4
storage temp. -20°C Freezer
solubility DMSO: ≥8mg/mL
form powder
color white to tan
CAS DataBase Reference319460-85-0(CAS DataBase Reference)
Safety Information
Hazard Codes Xn,N
Risk Statements 22-50/53
Safety Statements 60-61
WGK Germany 3
HS Code 29333990
MSDS Information
Axitinib Usage And Synthesis
FDA approved axitinib use of treating advanced kidney cancerJanuary 27, 2012, the FDA approved axitinib for the treatment of advanced kidney cancer (renal cell carcinoma) which other drugs unanswer . Inlyta is manufactured and sold by Pfizer,and is a oral pill taken twice a day.
Renal cell carcinoma is a type of tumor originating from the tubular endothelial cells. Axitinib can prevent certain protein called kinases playing a role in tumor growth and metastasis .
Axitinib is a small molecule tyrosine kinase inhibitor, effective against multiple targets, including VEGF receptors 1, 2 and 3.
Dr. Richard Pazdur, hematology and oncology drugs office director of FDA Drug Evaluation and Research Centre, said: "This is the seven kind of drugs allowed treating metastatic or advanced renal cell carcinoma since 2005 . Overall, during this time ,record level of drug development has dramatically changed the treatment of metastatic renal cell carcinoma paradigm, and offers a variety of treatment options for patients. "
In recent years, the drug has been approved for the treatment of kidney cancer include sorafenib (2005), sunitinib (2006), temsirolimus(2007), everolimus (2009), bevacizumab(2009) and pazopanib(2009).
The above information is edited by the chemicalbook of Tian Ye.
DescriptionIn January 2012, the US FDA approved axitinib (also referred to as AG-013736) for the treatment of advanced renal cell carcinoma (RCC) for patients who have not responded to prior therapy. Axitinib is a pan VEGF inhibitor and functions by binding to the intracellular tyrosine kinase catalytic domain of VEGF leading to blockade of signaling through this angiogenic pathway. Axitinib is50–400 times more potent for VEGF (enzyme Ki and cellular IC50s for VEGF 1, 2, and 3 are ~0.1 nM) than first-generation inhibitors like sorafenib and sunitinib. Axitinib also inhibits c-Kit and PDGFR(α/β) with enzyme Ki's of ~2 nM and was selective when tested against a broad panel of other protein kinases. Axitinib was discovered by a structure-based drug design approach and binds to the kinase domain of VEGF in a DFG-out conformation. Axitinib blocks VEGF-2 phosphorylation up to 7 h postdose in vivo and inhibits endothelial cell proliferation in xenograft tumors implanted in mice. Synthetic routes to axitinib employing a Migita coupling to form the diaryl sulfide and a Heck reaction to install the 2-styrylpyridine moiety have been reported.
Chemical PropertiesOff-White Solid
OriginatorPfizer (United States)
UsesA tyrosine kinase inhibitor; used in cancer therapy.
UsesAxitinib (AG-013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively.
UsesAxitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively.
UsesAxitinib is a tyrosine kinase inhibitor. Axitinib is used in cancer therapy.
DefinitionChEBI: An indazole substituted at position 3 by a 2-(pyridin-2-yl)vinyl group and at position 6 by a 2-(N-methylaminocarboxy)phenylsulfanyl group. Used for the treatment of advanced renal cell carcinoma after failure of a first line systemic tr atment.
Brand nameInlyta
Axitinib Preparation Products And Raw materials
Tag:Axitinib(319460-85-0) Related Product Information
Tofacitinib lenvatinib Mesylate Neratinib CO-1686 BKM-120 Nilotinib hydrochloride anhydrous GZD 824 Cabozantinib Palbociclib Dacomitinib (PF299804) Lenvatinib Bosutinib Dasatinib Trametinib Sunitinib Malate Crizotinib Afatinib Axitinib